Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/21/21 (What's New)

Summary

  • After assuring adherence and lack of drug–drug and drug–food interactions, it is important to assess whether the person has a fully active boosted PI available
  • For those without a fully active boosted PI, genotypic scores and phenotypic clinical cutoffs have been established for many agents in long-standing drug classes to predict level of drug activity, including newer agents within these classes
  • Agents from new drug classes such as entry inhibitors, post-attachment inhibitors, and INSTIs are assumed to be fully active in those who are naive to them[Lalezari 2003; Steigbigel 2008]
    • Selecting Among Available Antiretrovirals

    Action required

    Keywords: Management of Treatment-Experienced Patients, Resistance Testing

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.